Key result
Angiopeptin-eluting stents appear safe and feasible with 0% MACE at one year.
Why the study?
Does angiopeptin-eluting stent implantation prevent restenosis and neointimal hyperplasia in patients with native de novo coronary lesions?
Does angiopeptin-eluting stent implantation prevent restenosis and neointimal hyperplasia in patients with native de novo coronary lesions?
The first human experience with angiopeptin-eluting stents demonstrates feasibility, safety, and modest neointimal hyperplasia in native de novo coronary lesions.
No takes yet. Share an insight, caveat, or question.
Hypothesis-generating for angiopeptin-eluting stents; should not yet change practice pending larger trials.
Kwok et al. (2005) studied Native de novo coronary lesions (n=14). Angiopeptin-eluting BiodivYsio DD PC-coated stent was evaluated on Major adverse cardiac events or target vessel failure. Angiopeptin-eluting stent implantation in native de novo coronary lesions was feasible and safe, with 0% major adverse cardiac events and 0% binary restenosis at 1-year follow-up.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: